Dr. Veltri served on the faculty
of microbiology and surgery of WVU from 1969-80, where his research
covered the areas of infectious diseases, immunology, and cancer
biomarkers. Dr. Veltri developed a fee for service clinical immunology
and virology diagnostic testing service for the WVU hospital's
department of clinical pathology that generated about $100,000
in revenue by 1980. Teaching responsibilities included medical,
dental, nursing and graduate level students in areas of microbiology,
virology, and cancer biology. He also trained and served as advisor
for eight MS and seven Ph.D. graduate students of microbiology
during his tenure at WVU. A total of seventeen Medical, Dental,
and Medical Technology students did research clerkships in Dr.
Veltri's laboratory during his tenure at WVU. He obtained more
than $1.0 Million in extramural research funding while at WVU.
Served as President of the WVU chapter of Sigma Xi and also received
an outstanding teacher's award in 1976.
In 1981-84 Dr. Veltri established an R&D team, which developed the first diagnostic application for liposomes that consisted of rapid (1-2 minutes) and sensitive (10-fold improvement to ng/ml) slide co-agglutination diagnostic kits for infectious and rheumatologic diseases. Three Class II, FDA approved 510K products were transferred to manufacturing and released to market based upon a proprietary and patented co-agglutination technology that employed a proprietary method to prepare protein-A coated Liposomes and combine them with antibody coated latex particles. The three FDA approved tests were for Streptococcal Group A, Rheumatoid arthritis, and Infectious Mononucleosis.
In 1984, Dr. Veltri founded the American Biotechnology Company in Rockville, MD (acquired by Theracel Corporation in 1988). We discovered two unique classes of L-Ascorbic acid derivatives based upon the use of an Aldol and Michael addition series of modifications performed at the C-2 position of the molecule (see patents 1,2,4,5, 7 and 8 above). These small molecules were all of very low toxicity, water-soluble and demonstrated a variety of biological activities including anti-cancer, anti-infectious and anti-inflammatory activity.
In 1996, Dr. Veltri and his R&D team commercialized the first statistical-based (Logistic Regression model) and patented algorithm to predict prostate cancer post-operative stage based upon pre-treatment quantitative biopsy pathology as well as DNA ploidy and quantitative nuclear grade information determined by image analysis. The product was Trademarked “UroScoreTM”, a term suggested by Dr. Veltri. There are three publications (reference # 51, 77 and 88 in the above bibliography) on the subject.
|B.A.||1961-63||Youngstown State University||Biology/Chemistry|
|M.S.||1963-65||West Virginia University||Microbiology|
|Ph.D.||1965-68||West Virginia University||Microbiology|
|Assistant Professor & Director of Research||West Virginia University Medical School, Div. of Otolaryngology and Department of microbiology||
|Associate Professor & Director of Research||West Virginia University Medical School, Div. of Otolaryngology and Department of microbiology||
|Professor & Director of Research||West Virginia University Medical School, Div. of Otolaryngology and Department of microbiology||
|Director of virology and special immunology fee for service WVU hospital diagnostic laboratory||West Virginia University Medical School and Department of Clinical Pathology||
|Director of R&D;||Cooper- Biomedical, Inc., Malvern, PA||
|Project Director||National Foundation for Cancer Research, Bethesda, MD||
|President/CEO||American Biotechnology Company, Rockville, MD||
|Executive Vice President & Chief Scientific Officer||Theracel, Inc., Rockville, MD||
|Vice President of R&D & Chief Scientific Officer||CytoDiagnostics, Inc., OKC, OK.||
|Vice President of R&D and General Manager of R&D||UroCor, Inc., OKC, OK.||
|Adjunct appointee in the department of pathology||Oklahoma University Health Sciences Center, OKC, OK.||
|Institutional Biosafety Committee||Oklahoma University Health Sciences Center, OKC, OK.||
|Governor of State of Oklahoma Health Research Committee member||State of Oklahoma Center for Advancement of Science and Technology (OCAST)||
|Biotechnology Advisory Committee||Oklahoma City Community College||
|Biomedical Engineering Advisory Board of the Department of Engineering||University of Central Oklahoma||
|Technical supervisor of UroCor Clinical Chemistry laboratory||UroCor, Inc.||
|Visiting Associate Professor||Johns Hopkins University School of Medicine||
|Associate Professor||Johns Hopkins University School of Medicine||
|1976||WVU School of Medicine outstanding teacher award|
|1979||Elected a Fellow of the American Academy of Ophthalmology and Otolaryngology|
Visiting professor of microbiology at the University of Chile in Santiago from July 28-August 8, 1981. I was one of three faculty that taught a course in viral oncogenesis and tumor immunology. My portion of the course consisted of eleven lectures, two seminars, and three laboratory sessions. Also, the faculty made me an honorary member of the Chilean Society of Microbiology.
|1975-76||President of the WVU Chapter of Sigma Xi, a research honorary. Initiated a interdisciplinary research competition in science for graduate students in the sciences.|
Certificate of Recognition from Governor Keating for his services in helping to advance science and technology in Oklahoma presented by Dr. William A Sibley, President of Oklahoma Center for the Advancement of Science and Technology (OCAST) on October 30, 2001. Also a letter of appreciation was included from Dr. Kathy Kocan on behalf of the Health Research Committee.